Skyrizi Subcutaneous (pens or syringes) — Medica
Psoriatic arthritis
Initial criteria
- age > 18 years
- Medication is prescribed by or in consultation with a rheumatologist or a dermatologist
Reauthorization criteria
- Patient has been established on therapy for at least 6 months
- Patient experienced a beneficial clinical response from baseline by at least one objective measure; OR patient experienced improvement in at least one symptom
Approval duration
Initial: 6 months; Reauthorization: 1 year